Assessing the Therapeutic Potential of Fecal Microbiota Transplantation in Steatotic Liver Disease: Current Insights and Future Pathways

This is the authors' abstract. We don't add key points for this paper.

To explain the relevance of Fecal Microbiota Transplantation (FMT) for the treatment of MASLD, the scientific evidence supporting its usefulness, and the difficulties of its translation into effective treatments for use in routine clinical practice. FMT has been proven effective and safe in other indications and several procedures have been tested for delivery of fecal microbiota to the intestine. The field awaits results from ongoing clinical trials to better understand the role of FMT in the management of MASLD. The pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is multifaceted, involving an intricate interaction among genetic predisposition, diet, environmental factors, lifestyle choices, and the gut microbiota (GM). The complexity of these interactions may explain the difficulties to obtain an effective pharmacological treatment for MASLD.